In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine).
about
Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerabilityTwo-dimensional infrared spectra reveal relaxation of the nonnucleoside inhibitor TMC278 complexed with HIV-1 reverse transcriptaseAn Odyssey in antiviral drug development-50 years at the Rega Institute: 1964-2014Computational drug design strategies applied to the modelling of human immunodeficiency virus-1 reverse transcriptase inhibitorsAn update on clinical utility of rilpivirine in the management of HIV infection in treatment-naïve patientsRilpivirine: a new non-nucleoside reverse transcriptase inhibitorCurrent perspectives on HIV-1 antiretroviral drug resistanceHIV-1 Reverse Transcriptase Structure with RNase H Inhibitor Dihydroxy Benzoyl Naphthyl Hydrazone Bound at a Novel SiteHigh-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations.Crystal engineering of HIV-1 reverse transcriptase for structure-based drug designCrystal Structure of tert -Butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in Complex with HIV-1 Reverse Transcriptase (RT) Redefines the Elastic Limits of the Non-nucleoside Inhibitor-Binding PocketA comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutantsDetecting Allosteric Sites of HIV-1 Reverse Transcriptase by X-ray Crystallographic Fragment ScreeningExtension into the entrance channel of HIV-1 reverse transcriptase—Crystallography and enhanced solubilityPicomolar Inhibitors of HIV Reverse Transcriptase Featuring Bicyclic Replacement of a Cyanovinylphenyl GroupA mechanistic and structural investigation of modified derivatives of the diaryltriazine class of NNRTIs targeting HIV-1 reverse transcriptaseApproved Antiviral Drugs over the Past 50 YearsHIV-1 RT Inhibitors with a Novel Mechanism of Action: NNRTIs that Compete with the Nucleotide SubstrateColloid formation by drugs in simulated intestinal fluid.Parameterization of an effective potential for protein-ligand binding from host-guest affinity data.Drug interactions with new and investigational antiretrovirals.Nevirapine once daily: pharmacology, metabolic profile and efficacy data of the new extended-release formulation.Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition.HIV-1 reverse transcriptase and antiviral drug resistance. Part 1.Expanding the Antimalarial Drug Arsenal-Now, But How?Diarylaniline derivatives as a distinct class of HIV-1 non-nucleoside reverse transcriptase inhibitorsLarge scale affinity calculations of cyclodextrin host-guest complexes: Understanding the role of reorganization in the molecular recognition process.Drug resistance in non-B subtype HIV-1: impact of HIV-1 reverse transcriptase inhibitors.Picomolar Inhibitors of HIV-1 Reverse Transcriptase: Design and Crystallography of Naphthyl Phenyl EthersSynthesis, biological activity, and crystal structure of potent nonnucleoside inhibitors of HIV-1 reverse transcriptase that retain activity against mutant forms of the enzyme.Addressing the malaria drug resistance challenge using flow cytometry to discover new antimalarials.Efficient discovery of potent anti-HIV agents targeting the Tyr181Cys variant of HIV reverse transcriptase.Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings.Switch to Rilpivirine/Emtricitabine/Tenofovir Single-Tablet Regimen of Human Immunodeficiency Virus-1 RNA-Suppressed Patients, Agence Nationale de Recherches sur le SIDA et les Hépatites Virales CO3 Aquitaine Cohort, 2012-2014Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agentsDiscovery of dimeric inhibitors by extension into the entrance channel of HIV-1 reverse transcriptaseMutagenesis of human immunodeficiency virus reverse transcriptase p51 subunit defines residues contributing to vinylogous urea inhibition of ribonuclease H activity.New option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir.Effects of rilpivirine on human adipocyte differentiation, gene expression, and release of adipokines and cytokines.Role of Ligand Reorganization and Conformational Restraints on the Binding Free Energies of DAPY Non-Nucleoside Inhibitors to HIV Reverse Transcriptase.
P2860
Q24628212-D137781A-F8CD-4AF1-9F51-36A3A50B0CB8Q24652663-650DF727-6403-4EDC-BB0E-A5BC45BCDA1DQ26771734-72866EE0-7854-4561-ADF3-599953408BB9Q26777448-E150859E-B143-4F81-B757-22413E702066Q26827791-DB709573-2EF5-406D-9949-5D003788C443Q26830730-1A3D27E4-EA8E-4946-AF17-88E69B24D9A9Q26852626-BC793E2F-2B85-42FF-A12D-783F74C1A246Q27640888-66AD3AFC-F681-4900-913C-4FBD947986C4Q27649731-1C316BD6-1877-4B94-9682-116BA9286E10Q27651402-3033E11E-29B2-4057-ABCA-D4D3318B586DQ27667348-D509F5FF-E177-4463-8DFC-BAE3DA387415Q27675380-7BCE3E2B-B17D-4299-B1D4-F9BDD5594911Q27675974-4132F519-4B3C-4DC9-944B-841B228CF9B0Q27679282-632A4A75-0839-4F1A-AF08-397EE5A6232DQ27680431-B3D54321-B78C-4005-AB99-73C4D3353D61Q27683249-80410AB2-33DC-45F8-8A38-C789542903FAQ27755387-9AFF0319-F575-43E9-912C-99F535259E8FQ28250395-95674AF8-463F-4691-A48C-FAFA47718C98Q30494603-100F4471-565B-4B49-A284-4D921F9BC7BBQ30986053-51FFBC4E-E45F-4659-A7A3-98B4E4FC1EA2Q33801821-0E206FD8-4E61-45E4-9FA8-6AE14482BE2BQ33850152-1494355B-1876-40D0-99FE-18C13D142889Q33896402-6D09F109-AD22-4E9A-96AE-4DA8E50F1574Q33900441-97BD6763-88A0-48EF-B8DB-612B7F492A91Q33916111-6B93C55E-E975-4BFB-8592-0344E2F8AD1CQ33996952-18BD86E9-1FAD-4D7F-8E81-55FD6D94F1EFQ34065083-C632FA14-22FE-483E-84B5-EB38B11A24F3Q34303603-F516288A-DD35-42B4-870A-56EF095A5B0EQ34519713-13250DA0-7469-4821-ABBA-02B9F296C684Q34674575-86B006E1-613E-4382-80C6-A66EE9723FBBQ35091523-589F8A29-2F60-44A3-81E8-CDD6672CA49FQ35243844-19D5082A-CA8E-4225-94B4-200065BC7173Q35557326-35F32164-7C8F-4AEB-BCFA-AB5447F542C4Q35628276-AE3E8715-C68A-4A78-BB5D-DC4C2E11D94FQ35673318-BE1FF03F-0FFA-475F-A811-ACA082F5C549Q35753013-F78605EB-72AF-49D1-8710-CDC6E5384107Q35763192-7DE66F8A-3FB2-4906-9FC3-EF3FB274C879Q35939695-2015B036-D799-495C-9C32-8AE9FE8338ABQ36018903-7CD35A6F-B03C-42E2-9095-F29C392CDAC3Q36029898-76085975-1498-44A9-8EC6-D271EF44AE47
P2860
In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine).
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
In search of a novel anti-HIV ...... itrile (R278474, rilpivirine).
@ast
In search of a novel anti-HIV ...... itrile (R278474, rilpivirine).
@en
type
label
In search of a novel anti-HIV ...... itrile (R278474, rilpivirine).
@ast
In search of a novel anti-HIV ...... itrile (R278474, rilpivirine).
@en
prefLabel
In search of a novel anti-HIV ...... itrile (R278474, rilpivirine).
@ast
In search of a novel anti-HIV ...... itrile (R278474, rilpivirine).
@en
P2093
P356
P1476
In search of a novel anti-HIV ...... itrile (R278474, rilpivirine).
@en
P2093
Art D Clark
Bart Medaer
Don Ludovici
Eddy Arnold
Elisabeth Pasquier
Fons De Knaep
Fred De Clerck
Frits Daeyaert
Hilde Bohets
P304
P356
10.1021/JM040840E
P407
P577
2005-03-01T00:00:00Z